USA – THREAD, a decentralized clinical trial company, has announced the acquisition of CureClick, a platform for recruiting trial participants.

THREAD’s latest acquisition is the company’s third in less than six months. In January, the company announced the acquisition of inVibe, which aims to use patient voice data for research. In November, THREAD acquired Modus Outcomes, a research design consultancy.

CureClick provides a platform for ambassadors representing various diseases or conditions to locate open clinical trials and share information about how to participate on social media.

John Reites, CEO of THREAD, said in a statement, “One of the advantages of decentralization is engaging patients from broader geographic areas and more diverse backgrounds into clinical research so that trials better represent real-world populations.”

THREAD is positioning the acquisition as a way to more easily enroll participants in decentralized clinical trials.

Integrating CureClick’s technology in the THREAD platform means a participant can quickly and easily go from being totally unaware of a potentially life-altering clinical trial to being enrolled and participating in that trial,” Nico Coetzee, chief marketing officer at CureClick, said in a statement.

Coetzee will serve as head of recruitment for THREAD. “This is a powerful step forward to modernizing research.”

Decentralized clinical trials, like other virtual care tools, became more popular during the COVID-19 pandemic as researchers and trial participants sought to limit in-person interaction.

Medable, another decentralized clinical trial platform, raised a massive US$304 million Series D investment in October of last year. Around the same time, Lightship announced a US$40 million funding round.

Science 37, a DCT company, went public in 2021 after a merger with a special purpose acquisition company.

Meanwhile, Alphabet’s life sciences subsidiary, Verily, acquired clinical trial management company SignalPath last year to expand Baseline, its clinical trial platform that includes technology for decentralized and hybrid trials.

Furthermore, Thermo Fisher Scientific Inc.’s PPD clinical research business and Matrix Clinical Trials, a Matrix Medical Network offering, have collaborated to bring clinical trials to patients through an innovative decentralized clinical trial (DCT) solution.

The company is deploying cutting-edge Matrix mobile research sites and expert clinical staff across the United States to assist in identifying, recruiting, and retaining trial participants while ensuring a positive patient experience.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE